Modeling Meropenem Treatment, Alone and in Combination with Daptomycin, for KPC-Producing Klebsiella pneumoniae Strains with Unusually Low Carbapenem MICs

被引：10

作者：

Gagetti, P. ^{[1
,2
]}

Pasteran, F. ^{[2
]}

Martinez, M. P. ^{[1
]}

Fatouraei, M. ^{[1
]}

Gu, J. ^{[1
]}

Fernandez, R. ^{[1
]}

Paz, L. ^{[1
]}

Rose, W. E. ^{[3
]}

Corso, A. ^{[2
]}

Rosato, A. E. ^{[1
]}

机构：

[1] Houston Methodist Res Inst, Houston, TX USA

[2] INEI ANLIS Dr Carlos Malbran, Serv Antimicrobianos, Buenos Aires, DF, Argentina

[3] Univ Wisconsin, Sch Pharm, Madison, WI USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2016年 / 60卷 / 08期

基金：

美国国家卫生研究院;

关键词：

STAPHYLOCOCCUS-AUREUS; IN-VITRO; THERAPY; PHARMACODYNAMICS; HETERORESISTANCE; SIMULATION; MORTALITY;

D O I：

10.1128/AAC.00168-16

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Klebsiella pneumoniae strains producing K. pneumoniae carbapenemase (KPC) cause serious infections in debilitated and immunocompromised patients and are associated with prolonged hospital stays and increased mortality rates. Daptomycin is a lipopeptide used against Staphylococcus aureus infection and considered inactive against Gram-negative bacteria. We investigated the effectiveness of a daptomycin-meropenem combination by synergy kill curve and a pharmacokinetic/pharmacodynamic model. The combination may represent a novel therapeutic strategy against infections caused by KPC-producing K. pneumoniae strains.

引用

页码：5047 / 5050

页数：4

共 16 条

[1] INVITRO MODEL FOR SIMULTANEOUS SIMULATION OF THE SERUM KINETICS OF 2 DRUGS WITH DIFFERENT HALF-LIVES [J].

BLASER, J .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1985, 15 :125-130

[2] Pharmacodynamics of Minocycline against Staphylococcus aureus in an In Vitro Pharmacokinetic Model [J].

Bowker, Karen E. ;

Noel, Alan R. ;

MacGowan, Alasdair P. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (12) :4370-4373

[3] Comparative pharmacodynamics of meropenem using an in-vitro model to simulate once, twice and three times daily dosing in humans [J].

Bowker, KE ;

Holt, HA ;

Lewis, RJ ;

Reeves, DS ;

MacGowan, AP .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 42 (04) :461-467

[4] What Is the Appropriate Meropenem MIC for Screening of Carbapenemase-Producing Enterobacteriaceae in Low-Prevalence Settings? [J].

Fattouh, Ramzi ;

Tijet, Nathalie ;

McGeer, Allison ;

Poutanen, Susan M. ;

Melano, Roberto G. ;

Patel, Samir N. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (03) :1556-1559

[5] β-Lactams Increase the Antibacterial Activity of Daptomycin against Clinical Methicillin-Resistant Staphylococcus aureus Strains and Prevent Selection of Daptomycin-Resistant Derivatives [J].

Mehta, Shrenik ;

Singh, Christopher ;

Plata, Konrad B. ;

Chanda, Palas K. ;

Paul, Arundhati ;

Riosa, Sarah ;

Rosato, Roberto R. ;

Rosato, Adriana E. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (12) :6192-6200

[6] Imipenem heteroresistance: high prevalence among Enterobacteriaceae Klebsiella pneumoniae carbapenemase producers [J].

Nodari, Carolina Silva ;

Ribeiro, Vanessa Bley ;

Barth, Afonso Luis .

JOURNAL OF MEDICAL MICROBIOLOGY, 2015, 64 :124-126

[7] Carbapenem resistance in Enterobacteriaceae: here is the storm! [J].

Nordmann, Patrice ;

Dortet, Laurent ;

Poirel, Laurent .

TRENDS IN MOLECULAR MEDICINE, 2012, 18 (05) :263-272

[8]

Petrosillo N, 2013, EXPERT REV ANTI-INFE, V11, P159, DOI [10.1586/eri.12.162, 10.1586/ERI.12.162]

[9] Carbapenemase-Producing Klebsiella pneumoniae, a Key Pathogen Set for Global Nosocomial Dominance [J].

Pitout, Johann D. D. ;

Nordmann, Patrice ;

Poirel, Laurent .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (10) :5873-5884

[10] Characteristics of Meropenem Heteroresistance in Klebsiella pneumoniae Carbapenemase (KPC)-Producing Clinical Isolates of K-pneumoniae [J].

Pournaras, Spyros ;

Kristo, Ioulia ;

Vrioni, Georgia ;

Ikonomidis, Alexandros ;

Poulou, Aggeliki ;

Petropoulou, Dimitra ;

Tsakris, Athanassios .

JOURNAL OF CLINICAL MICROBIOLOGY, 2010, 48 (07) :2601-2604

← 1 2 →